Puffin Point
VC Fund
London, United Kingdom
Puffin Point is a Family Office, with significant experience in staffing and marketplace apps.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Puffin Point invests in
Stages Puffin Point invests in
Countries Puffin Point invests in
Round sizes
Round size
- Seed
- $564k–$4M
- Series A
- $3M–$11M
- Venture - Series Unknown
- $1.7M–$5.8M
Investment Focus
Industry
- Recruiting 3 (23%)
- Health Care 3 (23%)
- SaaS 2 (15%)
- Marketplace 2 (15%)
- Biotechnology 2 (15%)
Stage
- Seed 5 (38%)
- Series A 5 (38%)
- Venture - Series Unknown 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $5.8M / Venture - Series Unknown / Jul 24, 2024 | ||
| Tendertec is an award winning AI venture opening the door to personalised, preventative, and cost-effective care. Established in 2017 by Dr. Afroditi Konidari and Rui Zhang, Tendertec develops room sensing technology to support independent living for elderly and vulnerable people. Its first product is a safety & monitoring system enabling careproviders to effectively monitor vulnerable people and make data-driven decisions that improve their quality of life and care. Tendertec has been awarded a €242K grant by the Welsh Government, won the “Disruptive Product” award by GE Healthcare at EIT Health and has been named one of Vodafone’s 5G DIG Top 20 start-ups with the most potential to take advantage of the advent of 5G internationally. | $563.6K / Seed / Jun 03, 2024 | ||
| Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $1.7M / Venture - Series Unknown / Mar 29, 2023 | ||
| MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies. | $4M / Seed / Dec 08, 2022 | ||
| Storm6 are specialists in global EdTech recruitment, connecting organisations with the talent to drive their mission. Launched in 2022 to service the EdTech industry, Storm6 connect specialist talent with businesses at the forefront of education technology innovation. Storm6 focus on placing senior talent into start-ups and scale ups acrossEurope, North America, and the APAC region. The EdTech industry has skyrocketed in recent years with the uptake of new digital technologies, IOT devices and cloud-enabled tools fostering collaboration in the classroom. From language learning, K12 and Higher Education through to smart devices and apps focused on providing universal access to digital classrooms; investment into EdTech continues to soar globally. Storm6’s mission is to be integral to the digital education revolution and provide highly specialised teams across Data & Analytics, Engineering, Product Management and Sales & Marketing. We are a leading provider of EdTech-focused information to clients for market compensation and best practice in Diversity, Equity & Inclusion, hiring and retention. Storm6 is a trading division of Levin Group. | $3M / Series A / Jul 18, 2022 | ||
| Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $5.1M / Series A / Dec 14, 2020 | ||
| Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $5.2M / Venture - Series Unknown / Dec 14, 2020 | ||
| Storm3 are specialists in Global HealthTech recruitment, connecting organizations with the talent to drive their mission. | $11M / Series A / Nov 01, 2020 | ||
| Storm4 are the leaders in global GreenTech recruitment, connecting organisations with the talent to drive their mission for a more sustainable tomorrow.Storm4 launched in 2020 and focuses on the GreenTech sector, working with businesses that are at the cutting edge of renewable energy tech, and ‘clean’ innovation. Green technology or‘cleantech’ refers to the sector creating environmentally friendly products or services that aim to reduce costs, energy consumption, waste, or negative effects on the environment. We recruit the talent that drive these company’s missions for a more sustainable tomorrow.Our highly specialised teams cover key GreenTech skillsets across C-Suite in Product Management, Data & Analytics, Finance & Operations, Engineering, DevOps.We are the leading provider of GreenTech-focused information to clients for market compensation and best practice in diversity, hiring and retention. | $3M / Series A / Nov 01, 2020 | ||
| Our platform enables your business to bring out-of-the-box home offices and on-site services to one employee or thousands – in just a couple of clicks. | $2.5M / Seed / Aug 30, 2020 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Puffin Point invest in?
Puffin Point invests primarily in Recruiting, Health Care and SaaS startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Puffin Point's check size?
Puffin Point typically joins rounds of $564k–$4M at Seed, $3M–$11M at Series A and $1.7M–$5.8M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Puffin Point participates in.
When did Puffin Point last invest?
The most recent investment recorded for Puffin Point closed in Jul 2024. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
